Identification of a novel cisplatin resistance gene in bladder cancer and potential inhibitors
- 2 November 2025
- journal article
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2278-2286
Abstract
Cisplatin-based regimens are indicated for the treatment of a broad spectrum of solid malignancies. Bladder cancer is among the solid malignancies in which cisplatin is used as the first-line treatment. Despite the high success rate of cisplatin therapy, a subset of patients experience poor prognosis and develop resistance to cisplatin. For this reason, there is still a need to find new drug targets to overcome cisplatin resistance and improve response in patients with bladder cancer. This study aimed to find a potential target to help restore bladder cancer sensitivity to cisplatin. First, two microarray datasets were analyzed to find the gene signatures related to cisplatin resistance. Akinase anchor protein 5 (AKAP5) gene was selected as a possible target in cisplatin resistance. To find a suitable AKAP5 inhibitor, a virtual screening of a FDA-approved library was performed and 5-methyltetrahydrofolate (5-MTHF) was selected for the subsequent investigation. Finally, the effect of AKAP inhibition on the cytotoxicity of cisplatin in 5637 cells was determined using the MTT assay. Molecular docking of the selected inhibitor against AKAP5 was performed to validate the virtual screening results and the docking scores were in line with the virtual screening results. Cotreatment with 5-MTHF significantly increased cytotoxicity in 5637 cells treated with 2.5 μM of cisplatin, compared to the groups not receiving 5-MTHF (PKeywords
This publication has 28 references indexed in Scilit:
- Meta‐analysis of microarray data to determine gene indicators involved in cisplatin resistance in non‐small cell lung cancerCancer Reports, 2024
- G protein-coupled estrogen receptor (GPER)/GPR30 forms a complex with the β1-adrenergic receptor, a membrane-associated guanylate kinase (MAGUK) scaffold protein, and protein kinase A anchoring protein (AKAP) 5 in MCF7 breast cancer cellsArchives of Biochemistry and Biophysics, 2024
- Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancersDrug Resistance Updates, 2024
- Pharmacological NF‐κB inhibition decreases cisplatin chemoresistance in muscle‐invasive bladder cancer and reduces cisplatin‐induced toxicities.Molecular Oncology, 2023
- Serum total folate, 5‐methyltetrahydrofolate and vitamin B12 concentrations on incident risk of lung cancerInternational Journal of Cancer, 2022
- Safety evaluation of calcium L-methylfolateToxicology Reports, 2019
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signallingBritish Journal of Cancer, 2013
- Introduction to Cancer ChemotherapeuticsChemical Reviews, 2009
- Assembly of an A kinase-anchoring protein–β 2 -adrenergic receptor complex facilitates receptor phosphorylation and signalingCurrent Biology, 2000